Prostate Cancer

• Diagnosis, Imaging, Screening
• General Information
• Risk Factors
• Risk Reduction
• Treatment

Prostate Cancer

Diagnosis, Imaging, and Screening

NEWS:

PSA Era Over as Prostate Cancer Screening

PSA Velocity Predicts Prostate Cancer Outcomes

Rapid rise in PSA may signal deadly cancer

Reliability of prostate cancer test in doubt

Study Finds Flaws In Prostate Cancer Test

ARTICLES:

Medical Tests for Prostate Problems

Prostate cancer: Does PSA level affect prognosis?

Prostate-Specific Antigen Blood Test (PSA Test)

Prostate-Specific Antigen (PSA) Test: Questions and Answers

PSA testing: Is it necessary?

JOURNAL ARTICLES:

Assessment of the Enhancement in Predictive Accuracy Provided by Systematic Biopsy in Predicting Outcome for Clinically Localized Prostate Cancer. (J Urol)

Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. (Urology)

Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy? (Eur Urol)

Characteristics of prostate cancers detected at low PSA levels. (Prostate)

Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL. (BJU Int)

Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC study. (Prostate Cancer Prostatic Dis)

Clinical risk factors and prognostic significance of local recurrence in cutaneous melanoma. (Br J Dermatol)

Color and power Doppler sonography in the diagnosis of prostate cancer: comparison between vascular density and total vascularity. (J Ultrasound Med)

Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. (BJU Int)

Contrast specific imaging in the detection and localization of prostate cancer. (World J Urol)

Controversies in prostate cancer screening. (J Urol)

Current status of PSA screening. Early detection of prostate cancer. (Can Fam Physician)

Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population. (Urology)

Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. (Mod Pathol)

Does transrectal ultrasound guided eight-core prostate biopsy improve cancer detection rates in patients with prostate-specific antigen levels of 4.1-10 ng/mL? (Int J Urol)

Dosimetric evaluation of MRI-based treatment planning for prostate cancer. (Phys Med Biol)

Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. (Urology)

Elevated Prostate-Specific Antigen Levels Up to 25 Years Prior to Death from Prostate Cancer (Cancer Epidemiology Biomarkers & Prevention)

Endorectal MR Imaging and MR Spectroscopic Imaging for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy: Preliminary Experience. (Radiology)

Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population. (Urology)

Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. (Am J Ther)

Extended and saturation needle biopsy for the diagnosis of prostate cancer. (Curr Urol Rep)

Factors predicting for urinary incontinence after prostate brachytherapy. (Int J Radiat Oncol Biol Phys)

Has there been a change in practice of screening for prostate cancer with prostate-specific antigen in Ontario? (Clin Biochem)

Identification of Clinically Significant Prostate Cancer by Prostate-Specific Antigen Screening (Arch Intern Med)

Is tumor volume an independent prognostic factor in clinically localized prostate cancer? (J Urol)

Long-term follow-up of radiotherapy for prostate cancer. (Int J Radiat Oncol Biol Phys)

Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis. (J Clin Oncol)

Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. (J Urol)

PET and prostate cancer. (World J Urol)

Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. (Clin Prostate Cancer)

Pretreatment Evaluation of Prostate Cancer: Role of MR Imaging and 1H MR Spectroscopy. (Radiographics)

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level 4.0 ng per Milliliter (NEJM)

Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4-10 ng/ml. (World J Urol)

Proper Cut-off Value of Free to Total PSA Ratio for Detection of Prostate Cancer in Korean Men. (Yonsei Med J)

[Prostate cancer and prostate specific antigen screening] (Minerva Med)

Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. (J Cell Biochem)

Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy. (J Urol)

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. (J Urol)

Prostate cancer screening and mortality: a case-control study (United States). (Cancer Causes Control)

Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. (Cancer)

Prostate specific antigen for screening for prostate cancer: an appraisal of thai reports. (Asian Pac J Cancer Prev)

Prostate-specific antigen doubling time among Japanese men in an annual health screening program. (Int J Urol)

Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. (Cancer)

Relationship of body mass index and prostate specific antigen in a population-based study. (Urol Oncol)

Searching the internet for information on prostate cancer screening: an assessment of quality. (Urology)

Second round results of the Finnish population-based prostate cancer screening trial. (Clin Cancer Res)

The association between patient age and prostate cancer stage and grade at diagnosis. (BJU Int)

The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. (BJU Int)

The Incidence of Prostate Cancer in Men With Prostate Specific Antigen Greater Than 4.0 Ng/Ml: A Randomized Study Of 6 Versus 12 Core Transperineal Prostate Biopsy. (J Urol)

THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS? (J Urol)

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. (J Urol)

The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less. (J Urol)

Trends in the presentation of cutaneous malignant melanoma over three decades at King's College Hospital, London. (Clin Exp Dermatol)

Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. (J Urol)

Underutilization of digital rectal examination when screening for prostate cancer. (Arch Intern Med)

Update on screening for prostate cancer with prostate-specific antigen. (Crit Rev Oncol Hematol)

[Usefulness of PSA and its fractions in the diagnosis of prostate cancer] (Med Clin (Barc))

Variation in patterns of practice in diagnosing screen-detected prostate cancer. (BJU Int)

Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations. (Urology)

Go to the top